NovoCure Ltd

Listed Company

NVCRCIK 0001645113NasdaqLarge AcceleratedSurgical & Medical Instruments & ApparatusFY ends Dec 31

Period

FY 2025

Revenue

$655.35M

Net Income

$-136.23M

Total Assets

$804.33M

Equity

$340.47M

Shares Out

115.82M

Op. Cash Flow

$-49.03M

NVCR$15.92−1.79% · past yearDBEQ Basic

Daily closing prices

Business

NovoCure Ltd is a global oncology company that develops and commercializes Tumor Treating Fields (TTFields) therapy, a proprietary platform using electric fields to kill cancer cells delivered via portable medical devices. The company markets three TTFields therapy devices—Optune Gio for glioblastoma, Optune Lua for non-small cell lung cancer and mesothelioma, and Optune Pax for pancreatic cancer—with FDA approvals and regulatory certifications in multiple countries including the U.S., EU, Japan, and Canada. NovoCure operates as a direct-to-patient distributor in most markets, providing device support and reimbursement assistance, while pursuing clinical trials to expand TTFields applications to additional solid tumors and indications.

Summary from 10-K filed 2026-02-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net revenues	655	605	509	538	535
Cost of revenues	167	137	128	115	115
Gross profit	488	468	381	423	420
Research, development and clinical studies	225	210	223	206	201
Sales and marketing	240	239	227	174	137
General and administrative	178	190	164	133	126
Total operating costs and expenses	642	639	614	512	464
Operating income (loss)	−154	−170	−233	−90	−44
Financial (expenses) income, net	18	39	41	8	−8
Total income (loss) before income taxes	−136	−131	−192	−82	−52
Income tax	−23,000	37	15	11	6
Net income (loss)	−136	−169	−207	−93	−58
Basic net income (loss) per ordinary share (in usd per share)	−1.22	−1.56	−1.95	−0.88	−0.56
Diluted net income (loss) per ordinary share (in usd per share)	−1.22	−1.56	−1.95	−0.88	−0.56
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)	111	108	106	105	103
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)	111	108	106	105	103

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	94	164	241	115	209
Short-term investments	354	796	670	854	729
Restricted cash	10	2	2	508,000	807,000
Trade receivables, net	89	74	61	86	94
Receivables and prepaid expenses	59	35	23	26	17
Inventories	41	35	38	29	24
Total current assets	647	1,107	1,034	1,112	1,074
Property and equipment, net	78	78	51	33	23
Field equipment, net	22	15	11	13	13
Right-of-use assets	47	27	35	24	18
Other long-term assets	11	15	14	11	12
Total long-term assets	158	134	112	80	66
Total assets	804	1,241	1,146	1,192	1,139
Convertible note	0	558	0	—	—
Trade payables	122	105	94	85	73
Other payables, lease liabilities and accrued expenses	101	93	85	74	70
Total current liabilities	223	756	179	159	143
Senior secured credit facility, net	195	97	0	—	—
Long term leases	42	20	27	19	13
Employee benefit liabilities	4	7	8	4	5
Total long-term liabilities	241	124	605	592	586
Total liabilities	464	881	784	750	729
Commitments and contingencies	—	—	—	—	—
Ordinary shares - No par value, Unlimited shares authorized; Issued and outstanding: 112,492,667 shares and 108,516,819 shares at December 31, 2025 and December 31, 2024 respectively;	0	0	0	0	0
Additional paid-in capital	1,634	1,520	1,353	1,222	1,100
Accumulated other comprehensive income (loss)	−3	−6	−5	−2	−3
Retained earnings (accumulated deficit)	−1,290	−1,154	−986	−778	−686
Total shareholders equity	340	360	362	441	410
Total liabilities and shareholders equity	804	1,241	1,146	1,192	1,139

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	15	11	11	11	10
Accrued interest	5	−651,000	−95,000	−2	−94,000
Asset write-downs and impairment of field equipment	5	1	493,000	955,000	649,000
Share-based compensation	105	160	116	107	95
Foreign currency remeasurement loss (gain)	1	−227,000	161,000	−3	3
Decrease (increase) in accounts receivables and prepaid expenses	−39	−26	29	3	—
Amortization of discount (premium)	−23	−26	−23	−2	3
Decrease (increase) in inventories	−6	3	−9	−4	2
Decrease (increase) in other long-term assets	11	7	4	7	5
Increase (decrease) in accounts payables and accrued expenses	19	19	15	14	28
Increase (decrease) in other long-term liabilities	−5	−6	−10	−8	−11
Net cash provided by (used in) operating activities	−49	−26	−73	31	83
Purchase of property, equipment and field equipment	−27	−43	−27	−21	−24
Proceeds from maturity of short-term investments	1,285	778	1,215	1,179	958
Purchase of short-term investments	−821	−875	−1,004	−1,298	−1,079
Net cash provided by (used in) investing activities	437	−140	184	−140	−145
Proceeds from issuance of shares, net	4	4	4	5	5
Proceeds from senior secured credit facility, net	100	97	0	0	—
Repayment and redemption of long-term debt	−561	−13	−10,000	−28,000	−26,000
Tax payments related to net settlements on equity awards	−146,000	0	0	—	—
Exercise of options	6	2	11	10	21
Net cash provided by (used in) financing activities	−451	90	16	15	26
Effect of exchange rate changes on cash, cash equivalents and restricted cash	394,000	−174,000	131,000	−97,000	−188,000
Increase (decrease) in cash, cash equivalents and restricted cash	−63	−76	127	−94	−37
Income taxes paid (refunded), net	31	23	14	5	3
Interest paid	13	8	6,000	41,000	101,000
Right-of-use assets obtained in exchange for lease liabilities	29	494,000	18	12	5
Purchase of property incurred but unpaid at period end	886,000	2	2	0	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is NovoCure Ltd's CIK number?

NovoCure Ltd's SEC CIK number is 0001645113 (1645113). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find NovoCure Ltd's SEC filings?

All of NovoCure Ltd's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did NovoCure Ltd last report earnings?

NovoCure Ltd (NVCR) most recently filed an earnings 8-K with the SEC on Apr 30, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001645113-26-000043). This is NovoCure Ltd's most recent earnings filing of record — not a forecast of its next earnings date.

What is NovoCure Ltd's most recent earnings 8-K?

NovoCure Ltd's latest earnings 8-K (Item 2.02) was filed Apr 30, 2026 under accession 0001645113-26-000043. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View NovoCure Ltd's latest earnings 8-K →
Look up any company's CIK number →